PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

KPNA2 is a potential diagnostic serum biomarker for epithelial ovarian cancer and correlates with poor prognosis.

Abstract This study aimed to determine whether serum karyopherin alpha 2 levels can be used as a diagnostic biomarker for epithelial ovarian carcinoma. Karyopherin alpha 2 protein was detected by enzyme-linked immunosorbent assay in serum samples from 162 epithelial ovarian carcinoma patients and 48 healthy controls. Serum karyopherin alpha 2 levels in epithelial ovarian carcinoma patients were significantly higher than in healthy controls ( p < 0.001). When a karyopherin alpha 2 serum level of 2.52 µg/mL was used as a cut-off, the sensitivity and specificity of the assay for diagnosing epithelial ovarian carcinoma were 71.4% and 81.2%, respectively. High serum karyopherin alpha 2 levels (>485 µg/mL) correlated with International Federation of Gynecology and Obstetrics stage ( p < 0.0001), lymphatic metastasis ( p = 0.045), overall survival ( p = 0.001), and disease-free progression ( p = 0.006). Serum karyopherin alpha 2 represents a potential diagnostic biomarker for epithelial ovarian carcinoma.
PMID
Related Publications

Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.

Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.

MiR-26b/KPNA2 axis inhibits epithelial ovarian carcinoma proliferation and metastasis through downregulating OCT4.

Significance of concentration of serum soluble vascular cell adhesion molecule-1 in epithelial ovarian carcinoma.

KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of FOXO3a.

Authors

Mayor MeshTerms

Prognosis

Keywords

Karyopherin alpha 2

biomarker

epithelial ovarian carcinoma

serum

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28651492
OWN - NLM
STAT- MEDLINE
DA  - 20170627
DCOM- 20170710
LR  - 20170713
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - KPNA2 is a potential diagnostic serum biomarker for epithelial ovarian cancer and
      correlates with poor prognosis.
PG  - 1010428317706289
LID - 10.1177/1010428317706289 [doi]
AB  - This study aimed to determine whether serum karyopherin alpha 2 levels can be
      used as a diagnostic biomarker for epithelial ovarian carcinoma. Karyopherin
      alpha 2 protein was detected by enzyme-linked immunosorbent assay in serum
      samples from 162 epithelial ovarian carcinoma patients and 48 healthy controls.
      Serum karyopherin alpha 2 levels in epithelial ovarian carcinoma patients were
      significantly higher than in healthy controls ( p &lt; 0.001). When a karyopherin
      alpha 2 serum level of 2.52 microg/mL was used as a cut-off, the sensitivity and 
      specificity of the assay for diagnosing epithelial ovarian carcinoma were 71.4%
      and 81.2%, respectively. High serum karyopherin alpha 2 levels (&gt;485 microg/mL)
      correlated with International Federation of Gynecology and Obstetrics stage ( p &lt;
      0.0001), lymphatic metastasis ( p = 0.045), overall survival ( p = 0.001), and
      disease-free progression ( p = 0.006). Serum karyopherin alpha 2 represents a
      potential diagnostic biomarker for epithelial ovarian carcinoma.
FAU - Huang, Long
AU  - Huang L
AD  - 1 Department of Gynecology, Sun Yat-Sen University Cancer Center, Guangzhou,
      China.
AD  - 2 State Key Laboratory of Oncology in South China, Guangzhou, China.
AD  - 3 Department of Oncology, The Second Affiliated Hospital, Nanchang University,
      Nanchang, China.
FAU - Zhou, Yun
AU  - Zhou Y
AD  - 1 Department of Gynecology, Sun Yat-Sen University Cancer Center, Guangzhou,
      China.
AD  - 2 State Key Laboratory of Oncology in South China, Guangzhou, China.
AD  - 4 Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Cao, Xin-Ping
AU  - Cao XP
AD  - 2 State Key Laboratory of Oncology in South China, Guangzhou, China.
AD  - 4 Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
AD  - 5 Department of Radiation, Sun Yat-Sen University Cancer Center, Guangzhou,
      China.
FAU - Lin, Jia-Xin
AU  - Lin JX
AD  - 6 Department of Oncology, Guangdong General Hospital, Guangzhou, China.
FAU - Zhang, Lan
AU  - Zhang L
AD  - 1 Department of Gynecology, Sun Yat-Sen University Cancer Center, Guangzhou,
      China.
AD  - 2 State Key Laboratory of Oncology in South China, Guangzhou, China.
AD  - 4 Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Huang, Shu-Ting
AU  - Huang ST
AD  - 1 Department of Gynecology, Sun Yat-Sen University Cancer Center, Guangzhou,
      China.
AD  - 2 State Key Laboratory of Oncology in South China, Guangzhou, China.
AD  - 4 Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Zheng, Min
AU  - Zheng M
AD  - 1 Department of Gynecology, Sun Yat-Sen University Cancer Center, Guangzhou,
      China.
AD  - 2 State Key Laboratory of Oncology in South China, Guangzhou, China.
AD  - 4 Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (KPNA2 protein, human)
RN  - 0 (alpha Karyopherins)
RN  - Ovarian epithelial cancer
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neoplasms, Glandular and Epithelial/*blood/pathology
MH  - Ovarian Neoplasms/*blood/pathology
MH  - *Prognosis
MH  - alpha Karyopherins/*blood
OTO - NOTNLM
OT  - Karyopherin alpha 2
OT  - biomarker
OT  - epithelial ovarian carcinoma
OT  - serum
EDAT- 2017/06/28 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/06/28 06:00
AID - 10.1177/1010428317706289 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317706289. doi: 10.1177/1010428317706289.